[go: up one dir, main page]

WO2011004387A3 - Process for the preparation of dexlansoprazole polymorphic forms - Google Patents

Process for the preparation of dexlansoprazole polymorphic forms Download PDF

Info

Publication number
WO2011004387A3
WO2011004387A3 PCT/IN2010/000415 IN2010000415W WO2011004387A3 WO 2011004387 A3 WO2011004387 A3 WO 2011004387A3 IN 2010000415 W IN2010000415 W IN 2010000415W WO 2011004387 A3 WO2011004387 A3 WO 2011004387A3
Authority
WO
WIPO (PCT)
Prior art keywords
dexlansoprazole
preparation
polymorphic forms
amorphous
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2010/000415
Other languages
French (fr)
Other versions
WO2011004387A2 (en
Inventor
Ramakoteswara Rao Jetti
Neelima Bhagavatula
Saswata Lahiri
Lakshmana Rao Vadali
Swamy Saidugari
Veera Narayana Bandlamudi
Shankar Rama
Seshardi Rao Manukonda
Srinivasa Rao P. V.
Debashish Datta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Laboratories Ltd
Original Assignee
Matrix Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Laboratories Ltd filed Critical Matrix Laboratories Ltd
Publication of WO2011004387A2 publication Critical patent/WO2011004387A2/en
Publication of WO2011004387A3 publication Critical patent/WO2011004387A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a novel process for the preparation of amorphous Dexlansoprazole formula (I): from Dexlansoprazole solvate. The present invention also relates to novel processes for the preparation of polymorphic forms IV, Vl, amorphous, anhydrous and hemihydrate forms of Dexlansoprazole.
PCT/IN2010/000415 2009-06-18 2010-06-17 Process for the preparation of dexlansoprazole polymorphic forms Ceased WO2011004387A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN1436CH2009 2009-06-18
IN1436/CHE/2009 2009-06-18
IN2408CH2009 2009-10-05
IN2408/CHE/2009 2009-10-05
IN359CH2010 2010-02-15
IN0359/CHE/2010 2010-02-15

Publications (2)

Publication Number Publication Date
WO2011004387A2 WO2011004387A2 (en) 2011-01-13
WO2011004387A3 true WO2011004387A3 (en) 2011-06-23

Family

ID=43218704

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000415 Ceased WO2011004387A2 (en) 2009-06-18 2010-06-17 Process for the preparation of dexlansoprazole polymorphic forms

Country Status (1)

Country Link
WO (1) WO2011004387A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1395118B1 (en) 2009-07-29 2012-09-05 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF CRYSTALLINE DEXLANSOPRAZOLE
US20140357870A1 (en) * 2011-06-21 2014-12-04 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CN105017216A (en) * 2014-04-16 2015-11-04 天津药物研究院 Dexlansoprazole crystal form III and preparation method and application thereof
US10258639B2 (en) 2014-05-06 2019-04-16 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy
CN105017218A (en) * 2015-07-01 2015-11-04 合肥安德生制药有限公司 R-lansoprazole crystal form and preparation method therefor
IT201700050223A1 (en) * 2017-05-09 2018-11-09 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF CRYSTALLINE DEXLANSOPRAZOLE
WO2024153744A1 (en) 2023-01-20 2024-07-25 Institut National de la Santé et de la Recherche Médicale Autophagy activators for the treatment of rhabdomyolysis

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021201A1 (en) * 1996-11-14 1998-05-22 Takeda Chemical Industries, Ltd. Crystals of benzimidazole derivatives and their production
WO2002044167A1 (en) * 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Process for the crystallization of (r)- or (s)-lansoprazole
WO2003082857A2 (en) * 2002-03-27 2003-10-09 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
WO2004083200A1 (en) * 1999-06-17 2004-09-30 Akira Fujishima Crystalline form of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
EP1552833A1 (en) * 2002-10-16 2005-07-13 Takeda Chemical Industries, Ltd. Stable solid preparations
WO2009117489A1 (en) * 2008-03-18 2009-09-24 Dr. Reddy's Laboratories Ltd. Dexlansoprazole process and polymorphs
EP2216333A2 (en) * 2009-02-06 2010-08-11 Dipharma Francis S.r.l. Crystalline forms of Dexlansoprazole
WO2010104314A2 (en) * 2009-03-09 2010-09-16 한미약품 주식회사 Method for preparing non-crystalline (+)-lansoprazole and (+)-lansoprazole alcoholate used in same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (en) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd Pyridine derivative and preparation thereof
DE4035455A1 (en) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab ENANTIOMER SEPARATION
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
JP3828648B2 (en) 1996-11-14 2006-10-04 武田薬品工業株式会社 Crystal of 2- (2-pyridylmethylsulfinyl) benzimidazole compound and process for producing the same
JP2002501897A (en) 1998-01-30 2002-01-22 セプラコール， インク． R-lansoprazole compositions and methods
CN100562318C (en) 2000-05-15 2009-11-25 武田药品工业株式会社 Crystal preparation method
AU2001276721A1 (en) 2000-08-04 2002-02-18 Takeda Chemical Industries Ltd. Salts of benzimidazole compound and use thereof
BRPI0821386A2 (en) 2007-12-18 2015-06-16 Watson Pharma Private Ltd Process for the preparation of stable amorphous r-lansoprazole
JP2011507977A (en) 2007-12-31 2011-03-10 武田薬品工業株式会社 Solvated crystal form of (R) -2-[[[3-Methyl-4- (2,2,2-trifluoroethoxy) -2-pyridinyl] methyl] sulfinyl] -1H-benzimidazole
NZ588379A (en) 2008-03-10 2012-07-27 Takeda Pharmaceutical Crystal of benzimidazole compound

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021201A1 (en) * 1996-11-14 1998-05-22 Takeda Chemical Industries, Ltd. Crystals of benzimidazole derivatives and their production
WO2004083200A1 (en) * 1999-06-17 2004-09-30 Akira Fujishima Crystalline form of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
WO2002044167A1 (en) * 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Process for the crystallization of (r)- or (s)-lansoprazole
WO2003082857A2 (en) * 2002-03-27 2003-10-09 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
EP1552833A1 (en) * 2002-10-16 2005-07-13 Takeda Chemical Industries, Ltd. Stable solid preparations
WO2009117489A1 (en) * 2008-03-18 2009-09-24 Dr. Reddy's Laboratories Ltd. Dexlansoprazole process and polymorphs
EP2216333A2 (en) * 2009-02-06 2010-08-11 Dipharma Francis S.r.l. Crystalline forms of Dexlansoprazole
WO2010104314A2 (en) * 2009-03-09 2010-09-16 한미약품 주식회사 Method for preparing non-crystalline (+)-lansoprazole and (+)-lansoprazole alcoholate used in same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2010, JANG, SUN YOUNG ET AL: "Method for preparing non- crystalline (+)-lansoprazole and (+)-lansoprazole alcoholate used in same", XP002614116, retrieved from STN Database accession no. 2010:1161381 *

Also Published As

Publication number Publication date
WO2011004387A2 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
WO2010102980A8 (en) Process for preparing substituted 2-nitrobiphenyls
WO2011039108A3 (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
WO2011004387A3 (en) Process for the preparation of dexlansoprazole polymorphic forms
WO2011022596A3 (en) Preparation of bazedoxifene and its salts
WO2010139981A3 (en) Processes for preparing crystalline forms of dasatinib
WO2012015999A3 (en) Process for the preparation of imatinib mesylate
WO2011024192A3 (en) Novel polymorphs of raltegravir
WO2010076810A3 (en) A process for the preparation of gefitinib
EP2280039B8 (en) Process for production of polysilane compound
WO2011015882A3 (en) Anhydrate of triotropium bromide
WO2011015287A3 (en) Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
WO2010123545A3 (en) Angiogenesis inhibitors
MX2011009898A (en) Process for the preparation of propionic acid derivatives.
WO2010004578A3 (en) Novel and improved processes for the preparation of paliperidone
UA106988C2 (en) A method of obtaining of 1-benzyl-3-hydroxymethyl-1h-indazole and its derivatives and required intermediate magnesium compounds
WO2010121877A3 (en) Process for the preparation of olopatadine
MX2012002818A (en) Novel method for synthesizing ivabradine and the addition salts thereof with a pharmaceutically acceptable acid.
WO2010083996A8 (en) A process for preparing memantine
WO2011018771A3 (en) Process for the preparation of valganciclovir hydrochloride
WO2011058524A3 (en) Crystalline forms of bosentan salts and processes for their preparation
WO2009060297A3 (en) An improved process for the preparation of paliperidone and its intermediates
WO2009147626A3 (en) Anhydrous amorphous form of imatinib mesylate
WO2010146595A3 (en) Novel polymorphs of flibanserin hydrochloride
WO2011100282A3 (en) Imatinib mesylate polymorphs
TN2012000154A1 (en) Process for the manufacture of organic compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10768081

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10768081

Country of ref document: EP

Kind code of ref document: A2